OBJECTIVE: To describe the management strategies and outcomes of patients with renal medullary carcinoma (RMC) and characterise predictors of overall survival (OS). PATIENTS AND METHODS: RMC is a rare and aggressive malignancy that afflicts young patients with sickle cell trait; there are limited data on management to date. This is a study of patients with RMC who were treated in 2000-2015 at eight academic institutions in North America and France. The Kaplan-Meier method was used to estimate OS, measured from initial RMC diagnosis to date of death. Cox regression analysis was used to determine predictors of OS. RESULTS: In all, 52 patients (37 males) were identified. The median (range) age at diagnosis was 28 (9-48) years and 49 patients (94%) had stage III/IV. The median OS for all patients was 13.0 months and 38 patients (75%) had nephrectomy. Patients who underwent nephrectomy had superior OS compared to patients who were treated with systemic therapy only (median OS 16.4 vs 7.0 months, P < 0.001). In all, 45 patients received chemotherapy and 13 (29%) had an objective response; 28 patients received targeted therapies, with 8-week median therapy duration and no objective responses. Only seven patients (13%) survived for >24 months. CONCLUSIONS: RMC carries a poor prognosis. Chemotherapy provides palliation and remains the mainstay of therapy, but <20% of patients survive for >24 months, underscoring the need to develop more effective therapy for this rare tumour. In this study, nephrectomy was associated with improved OS.
OBJECTIVE: To describe the management strategies and outcomes of patients with renal medullary carcinoma (RMC) and characterise predictors of overall survival (OS). PATIENTS AND METHODS: RMC is a rare and aggressive malignancy that afflicts young patients with sickle cell trait; there are limited data on management to date. This is a study of patients with RMC who were treated in 2000-2015 at eight academic institutions in North America and France. The Kaplan-Meier method was used to estimate OS, measured from initial RMC diagnosis to date of death. Cox regression analysis was used to determine predictors of OS. RESULTS: In all, 52 patients (37 males) were identified. The median (range) age at diagnosis was 28 (9-48) years and 49 patients (94%) had stage III/IV. The median OS for all patients was 13.0 months and 38 patients (75%) had nephrectomy. Patients who underwent nephrectomy had superior OS compared to patients who were treated with systemic therapy only (median OS 16.4 vs 7.0 months, P < 0.001). In all, 45 patients received chemotherapy and 13 (29%) had an objective response; 28 patients received targeted therapies, with 8-week median therapy duration and no objective responses. Only seven patients (13%) survived for >24 months. CONCLUSIONS:RMC carries a poor prognosis. Chemotherapy provides palliation and remains the mainstay of therapy, but <20% of patients survive for >24 months, underscoring the need to develop more effective therapy for this rare tumour. In this study, nephrectomy was associated with improved OS.
Authors: Lina Assad; Erika Resetkova; Victor L Oliveira; Wei Sun; John M Stewart; Ruth L Katz; Nancy P Caraway Journal: Cancer Date: 2005-02-25 Impact factor: 6.860
Authors: Mahul B Amin; Steven C Smith; Abbas Agaimy; Pedram Argani; Eva Marie Compérat; Brett Delahunt; Jonathan I Epstein; John N Eble; David J Grignon; Arndt Hartmann; Ondřej Hes; Michelle S Hirsch; Rafael E Jimenez; Lakshmi P Kunju; Guido Martignoni; Jesse K McKenney; Holger Moch; Rodolfo Montironi; Gladell P Paner; Priya Rao; John R Srigley; Satish K Tickoo; Victor E Reuter Journal: Am J Surg Pathol Date: 2014-07 Impact factor: 6.394
Authors: Sumanta K Pal; Toni K Choueiri; Kai Wang; Depinder Khaira; Jose A Karam; Eliezer Van Allen; Norma A Palma; Mark N Stein; Adrienne Johnson; Rachel Squillace; Julia A Elvin; Juliann Chmielecki; Roman Yelensky; Evgeny Yakirevich; Doron Lipson; Douglas I Lin; Vincent A Miller; Philip J Stephens; Siraj M Ali; Jeffrey S Ross Journal: Eur Urol Date: 2015-07-03 Impact factor: 20.096
Authors: Roula Albadine; Wenle Wang; Noel A Brownlee; Antoun Toubaji; Athanase Billis; Perdram Argani; Jonathan I Epstein; A Julian Garvin; Rima Cousi; Edward M Schaeffer; Christian Pavlovich; George J Netto Journal: J Urol Date: 2009-06-18 Impact factor: 7.450
Authors: Jacob S Lipkin; Syed M Rizvi; Zoran Gatalica; Nabeel E Sarwani; Sheldon L Holder; Mathew Kaag; Joseph J Drabick; Monika Joshi Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742
Authors: Kathryn E Beckermann; Deva Sharma; Shruti Chaturvedi; Pavlos Msaouel; Miguel R Abboud; Yves Allory; Franck Bourdeaut; Julien Calderaro; Aguirre A de Cubas; Vimal K Derebail; Andrew L Hong; Rakhi P Naik; Gabriel G Malouf; Elizabeth A Mullen; Victor E Reuter; Charles W M Roberts; Cheryl L Walker; Christopher G Wood; Michael R DeBaun; Hendrik Van Poppel; Nizar M Tannir; W Kimryn Rathmell Journal: J Oncol Pract Date: 2017-07 Impact factor: 3.840
Authors: David S Tourigny; Mark Zucker; Minsoo Kim; Paul Russo; Jonathan Coleman; Chung-Han Lee; Maria I Carlo; Ying-Bei Chen; A Ari Hakimi; Ritesh R Kotecha; Ed Reznik Journal: Front Oncol Date: 2022-06-28 Impact factor: 5.738
Authors: Pavlos Msaouel; Andrew L Hong; Elizabeth A Mullen; Michael B Atkins; Cheryl Lyn Walker; Chung-Han Lee; Marcus A Carden; Giannicola Genovese; W Marston Linehan; Priya Rao; Maria J Merino; Howard Grodman; Jeffrey S Dome; Conrad V Fernandez; James I Geller; Andrea B Apolo; Najat C Daw; H Courtney Hodges; Marva Moxey-Mims; Darmood Wei; Donald P Bottaro; Michael Staehler; Jose A Karam; W Kimryn Rathmell; Nizar M Tannir Journal: Clin Genitourin Cancer Date: 2018-09-12 Impact factor: 2.872
Authors: Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou Journal: Mod Pathol Date: 2021-03-04 Impact factor: 8.209
Authors: Kathryn E Beckermann; Pradeep C Jolly; Ju Y Kim; Jennifer Bordeaux; Igor Puzanov; W Kimryn Rathmell; Douglas B Johnson Journal: J Immunother Cancer Date: 2017-01-17 Impact factor: 13.751
Authors: Pavlos Msaouel; Gabriel G Malouf; Xiaoping Su; Hui Yao; Durga N Tripathi; Melinda Soeung; Jianjun Gao; Priya Rao; Cristian Coarfa; Chad J Creighton; Jean-Philippe Bertocchio; Selvi Kunnimalaiyaan; Asha S Multani; Jorge Blando; Rong He; Daniel D Shapiro; Luigi Perelli; Sanjana Srinivasan; Federica Carbone; Patrick G Pilié; Menuka Karki; Riyad N H Seervai; Bujamin H Vokshi; Dolores Lopez-Terrada; Emily H Cheng; Ximing Tang; Wei Lu; Ignacio I Wistuba; Timothy C Thompson; Irwin Davidson; Virginia Giuliani; Katharina Schlacher; Alessandro Carugo; Timothy P Heffernan; Padmanee Sharma; Jose A Karam; Christopher G Wood; Cheryl L Walker; Giannicola Genovese; Nizar M Tannir Journal: Cancer Cell Date: 2020-04-30 Impact factor: 31.743